

SHEET 1 of 3

Form PTO-1449 (March 2003)

U.S. Department of
Patent and TrademarkAtty. Docket No.
EYE-010CONSerial No.
10/786,491

MAR 15 2004

INFORMATION DISCLOSURE
STATEMENTApplicant
David R. GuyerFiling Date
02/25/2004

Group

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

KC ↓ ✓	C1	Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharmaceutical Research 2000;17(12):1503-10.
	C2	Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbio Immunol 1999;237:97-132.
	C3	Ferrara N, Houck K, Jakeman L, et al. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991;47:211-18.
	C4	Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-4.
	C5	Funatsu H, Hidetoshi Y, Hidetaka N, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002a;133(1):70-7.

EXAMINER

DATE CONSIDERED

3/13/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) U.S. Department of Patent and Trademark INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>	Any. Docket No. EYE-010CON	Serial No. 10/786,491
	Applicant David R. Guyer	
	Filing Date 02/25/2004	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
KC	C6	Funatsu H, Yamashita H, Nakashini Y, et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of subjects with proliferative diabetic retinopathy. Br J Ophthalmol 2002b;86(3):311-15.
	C7	Hofman P, Harriet GT, Blaauwgeers MJ, et al. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Current Eye Research 2000;21(2):637-45.
	C8	Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-62.
	C9	Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120(3):338-46.
	C10	Kvanta A, Algreve PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Visual Sci 1996;37:1929-34.
	C11	Leung DW, Cachianes G, Kuang W-J, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
	C12	Lip P-L, Blann AD, Path MRCP, et al. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology 2001;108:705-10.
	C13	Lopez PF, Sippi BD, Lambert MH, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Visual Sci 1996;37:855-68.
	C14	Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000;156:1733-9.
↓	C15	Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier break down in early diabetes. Invest Ophthalmol Vis Sci 2001;42(10):2408-13.

EXAMINER <i>Berg Chou</i>	DATE CONSIDERED <i>3/13/06</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)	U.S. Department of Patent and Trademark	Atty. Docket No. EYE-010CON	Serial No. 10/786,491
INFORMATION DISCLOSURE STATEMENT		Applicant David R. Guyer	
		Filing Date 02/25/2004	Group
<i>(Use several sheets if necessary)</i>			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
KC	C16	Ruckman J, Green LS, Beeson J, et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF ₁₆₅). J Biol Chem 1998;273:20556-67.
	C17	Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219(4587):983-5.
	C18	Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci 1996;37:1334-40.
	C19	Tucker CE, Chen L-S, Judkins MB, et al. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (EYE001) in rhesus monkeys. J Chromatog B. 1999;732:203-12.
↓	C20	Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of subjects with subretinal neovascularization. Br J Ophthalmol 1996;80:363-6.

EXAMINER <i>KberfChoy</i>	DATE CONSIDERED <i>3/13/06</i>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	